Tokyo, July 10, 2006 (JCN) - Takara Bio has entered into a licensing agreement with US company InVivoScribe Technologies for a patent on detecting the mutations of FMS-like tyrosine kinase 3 (FLT3) genes developed by Takara Bio. Under the agreement terms, InVivoScribe Technologies will receive an exclusive license to use the patent worldwide, except in Japan.
